Enhanced Axonal Metabolism during Early Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis

References

1. 1.↵
   2. Compston A,
   3. Coles A

   . Multiple sclerosis. Lancet 2008;372:1502–17

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Geurts JJ,
   3. Calabrese M,
   4. Fisher E, et al

   . Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurol 2012;11:1082–92

   CrossRefPubMedWeb of Science
3. 3.↵
   2. He J,
   3. Inglese M,
   4. Li BS, et al

   . Relapsing-remitting multiple sclerosis: metabolic abnormality in nonenhancing lesions and normal-appearing white matter at MR imaging: initial experience. Radiology 2005;234:211–17

   CrossRefPubMedWeb of Science
4. 4.↵
   2. van Walderveen MA,
   3. Barkhof F,
   4. Pouwels PJ, et al

   . Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann Neurol 1999;46:79–87

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Tartaglia MC,
   3. Narayanan S,
   4. DeStefano N, et al

   . Choline is increased in pre-lesional normal appearing white matter in multiple sclerosis. J Neurol 2002;249:1382–90

   CrossRefPubMedWeb of Science
6. 6.↵
   2. Caramanos Z,
   3. Narayanan S,
   4. Arnold DL

   . 1H-MRS quantification of tNA and tCr in patients with multiple sclerosis: a meta-analytic review. Brain 2005;128:2483–506

   Abstract/FREE Full Text
7. 7.↵
   2. Geurts JJ,
   3. Reuling IE,
   4. Vrenken H, et al

   . MR spectroscopic evidence for thalamic and hippocampal, but not cortical, damage in multiple sclerosis. Magn Reson Med 2006;55:478–83

   CrossRefPubMedWeb of Science
8. 8.↵
   2. Vrenken H,
   3. Barkhof F,
   4. Uitdehaag BM, et al

   . MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter. Magn Reson Med 2005;53:256–66

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Bellmann-Strobl J,
   3. Stiepani H,
   4. Wuerfel J, et al

   . MR spectroscopy (MRS) and magnetisation transfer imaging (MTI), lesion load and clinical scores in early relapsing remitting multiple sclerosis: a combined cross-sectional and longitudinal study. Eur Radiol 2009;19:2066–74

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Chard DT,
    3. Griffin CM,
    4. McLean MA, et al

    . Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain 2002;125:2342–52

    Abstract/FREE Full Text
11. 11.↵
    2. Yednock TA,
    3. Cannon C,
    4. Fritz LC, et al

    . Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha-4-beta-1 integrin. Nature 1992;356:63–66

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Miller DH,
    3. Soon D,
    4. Fernando KT, et al

    . MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007;68:1390–401

    CrossRef
13. 13.↵
    2. Polman CH,
    3. O'Connor PW,
    4. Havrdova E, et al

    . A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899–910

    CrossRefPubMedWeb of Science
14. 14.↵
    2. Khan O,
    3. Shen Y,
    4. Caon C, et al

    . Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler 2005;11:646–51

    Abstract/FREE Full Text
15. 15.↵
    2. Narayanan S,
    3. DeStefano N,
    4. Francis GS, et al

    . Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 2001;248:979–86

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Polman CH,
    3. Reingold SC,
    4. Edan G, et al

    . Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.” Ann Neurol 2005;58:840–46

    CrossRefPubMedWeb of Science
17. 17.↵
    2. Wiebenga OT,
    3. Klauser AM,
    4. Nagtegaal GJ, et al

    . Longitudinal absolute metabolite quantification of white and gray matter regions in healthy controls using proton MR spectroscopic imaging. NMR Biomed 2014;27:304–11

    CrossRefPubMed
18. 18.↵
    2. Steenwijk MD,
    3. Pouwels PJ,
    4. Daams M, et al

    . Accurate white matter lesion segmentation by k nearest neighbor classification with tissue type priors (kNN-TTPs). Neuroimage Clin 2013;3:462–69

    CrossRefPubMed
19. 19.↵
    2. Chard DT,
    3. Jackson JS,
    4. Miller DH, et al

    . Reducing the impact of white matter lesions on automated measures of brain gray and white matter volumes. J Magn Reson Imaging 2010;32:223–28

    CrossRefPubMed
20. 20.↵
    2. Provencher SW

    . Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30:672–79

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Maudsley AA,
    3. Domenig C,
    4. Govind V, et al

    . Mapping of brain metabolite distributions by volumetric proton MR spectroscopic imaging (MRSI). Magn Reson Med 2009;61:548–59

    CrossRefPubMed
22. 22.↵
    2. Tal A,
    3. Kirov II,
    4. Grossman RI, et al

    . The role of gray and white matter segmentation in quantitative proton MR spectroscopic imaging. NMR Biomed 2012;25:1392–400

    CrossRefPubMedWeb of Science
23. 23.↵
    2. Gasparovic C,
    3. Yeo R,
    4. Mannell M, et al

    . Neurometabolite concentrations in gray and white matter in mild traumatic brain injury: an 1H-magnetic resonance spectroscopy study. J Neurotrauma 2009;26:1635–43

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Ciccarelli O,
    3. Altmann DR,
    4. McLean MA, et al

    . Spinal cord repair in MS: does mitochondrial metabolism play a role? Neurology 2010;74:721–27

    CrossRef
25. 25.↵
    2. Witte ME,
    3. Geurts JJ,
    4. de Vries HE, et al

    . Mitochondrial dysfunction: a potential link between neuroinflammation and neurodegeneration? Mitochondrion 2010;10:411–18

    CrossRefPubMedWeb of Science
26. 26.↵
    2. Nikić I,
    3. Merkler D,
    4. Sorbara C, et al

    . A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med 2011;17:495–99

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Dalton CM,
    3. Miszkiel KA,
    4. Barker GJ, et al

    . Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol 2004;251:407–13

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Fox RJ,
    3. Cronin T,
    4. Lin J, et al

    . Measuring myelin repair and axonal loss with diffusion tensor imaging. AJNR Am J Neuroradiol 2011;32:85–91

    Abstract/FREE Full Text
29. 29.↵
    2. Mellergård J,
    3. Tisell A,
    4. Dahlqvist LO, et al

    . Association between change in normal appearing white matter metabolites and intrathecal inflammation in natalizumab-treated multiple sclerosis. PLoS One 2012;7:e44739

    CrossRefPubMed
30. 30.↵
    2. Srinivasan R,
    3. Sailasuta N,
    4. Hurd R, et al

    . Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 2005;128:1016–25

    Abstract/FREE Full Text
31. 31.↵
    2. Mader I,
    3. Roser W,
    4. Kappos L, et al

    . Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study. AJNR Am J Neuroradiol 2000;21:1220–27

    Abstract/FREE Full Text
32. 32.↵
    2. Pouwels PJ,
    3. Frahm J

    . Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magn Reson Med 1998;39:53–60

    CrossRefPubMedWeb of Science
33. 33.↵
    2. Chard DT,
    3. McLean MA,
    4. Parker GJ, et al

    . Reproducibility of in vivo metabolite quantification with proton magnetic resonance spectroscopic imaging. J Magn Reson Imaging 2002;15:219–25

    CrossRefPubMedWeb of Science
34. 34.↵
    2. Kreis R

    . Issues of spectral quality in clinical 1H-magnetic resonance spectroscopy and a gallery of artifacts. NMR Biomed 2004;17:361–81

    CrossRefPubMedWeb of Science